Industry news

• Biotech CEOs pen standards for coronavirus trials, data disclosures amid FDA reputation crisis

  04 September 2020 Eric Sagonowsky / FirecePharma

  Amid doubts about the FDA’s decision-making process during the pandemic, biotech CEOs on the front lines of research are laying out their approach and asking “all parties” involved in the process to adhere to high scientific standards. 

• How digitalisation can help pharma weather the COVID-19 storm

  04 September 2020 Andrew Dunbar / European Pharmaceutical Review

  Just a few months into this ‘new normal’, it is already clear that digital tech will have a pivotal role to play in ensuring that the pharma industry continues to function to the best of its abilities, providing both healthcare practitioners (HCPs) and patients with the vital support they need. Here are five digital technologies that pharma companies will need to embrace to remain relevant.

• In vitro diagnostics and the coronavirus pandemic

  03 September 2020 Liz Thorn / European Pharmaceutical Review

  Now is the time for in vitro diagnostics (IVD). The coronavirus pandemic is offering an unprecedented opportunity to demonstrate the true benefit of these diagnostics in the modern world.

• Russia Ready to Provide all the Necessary Information on “Sputnik V” Vaccine to WHO

  03 September 2020 GMP News

  Russia is ready to provide all the necessary data on its coronavirus vaccine to the World Health Organization (WHO), Russia’s Permanent Representative to the United Nations Geneva office and other Geneva-based international organizations Gennady Gatilov said in an open interview with TASS First Deputy Director General Mikhail Gusman.

• Automated Insulin Delivery and Monitoring System Approved for Use in Young Pediatric Patients

  02 September 2020 GMP News

  The U.S. Food and Drug Administration approved the MiniMed 770G System, a hybrid closed loop diabetes management device that is intended to automatically monitor glucose (sugar) and provide appropriate basal insulin doses with little or no input from the users or their caregivers for use by individuals aged 2 to 6 with type 1 diabetes.

• A Culture of Cells Producing Antibodies against COVID-19 was Created in Russia

  02 September 2020 GMP News

  Specialists of the Institute of Bioorganic Chemistry of the Russian Academy of Sciences have grown a mouse cell culture capable of producing large amounts of antibodies to one of the key proteins of the coronavirus, potentially suitable for COVID-19 treatment and use in diagnostic systems.

• Scientists from NCFU have Improved the Natural Properties of Substances to Treat Malaria, Cancer

  01 September 2020 GMP News

  Scientists from the North-Caucasus Federal University (NCFU) have created a method for synthesizing an analogue of a natural substance used to fight malaria and cancer cells. Work at the atomic level made it possible to enhance the properties of the substance and make it more accessible.

• Large-scale Deliveries of the “Sputnik V” Vaccine will Start in September

  01 September 2020 GMP News

  “As for vaccination against the coronavirus infection, right now simultaneously the increase in production and the post-registration observation are underway. First of all, of course, the vaccines will be supplied for healthcare workers and instructors, this [vaccination] will be absolutely voluntary. The first large batches will be supplied as early as September,” Russian Healthcare Minister Mikhail Murashko told journalists.

• Russia to Supply over 2 million Doses of its COVID-19 Vaccine to Kazakhstan

  31 August 2020 GMP News

  The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and SK-Pharmacy, a Kazakh company, have announced an agreement for the supply of the Russian Sputnik V vaccine to Kazakhstan.

• Second Russian COVID-19 Vaccine May Be Registered in October

  31 August 2020 GMP News

  The first batch of a newly-developed vaccine against the novel coronavirus, developed by the state research center of virology and biotechnology Vektor, may be available at the end of October or early November, the chief of the center’s zoonotic infections and influenza section, Alexander Ryzhikov, told the Rossiya-24 round-the-clock television news channel in an interview.